Moderna's mRNA Flu Vaccine Outperforms Standard Shot in Late-Stage Trial

mRNA-1010 superior to standard-dose vaccine for preventing flu, finds study

For adults aged 50 years or older, an investigational messenger RNA (mRNA)-based vaccine (mRNA-1010) is superior to standard-dose licensed vaccines for preventing influenza-like illness, according to a study published in the New England Journal of Medicine.

Moderna mRNA flu vaccine beats standard shot, awaits FDA review

After a large trial showed stronger protection, regulators are weighing whether Moderna’s mRNA vaccine could become a U.S. first.

New Trials: Moderna Performed About 27% Better Than Standard Flu Vaccines

Some years, flu shots only reduce the risk of illness by as little as 20% to 30%. Messenger RNA technology, or mRNA, is widely seen as a promising way to improve their efficacy, partly because it can be updated more quickly to match circulating strains. New results published Wednesday in the New England Journal of Medicine found Moderna’s mRNA flu vaccine gave more protection against illness than the standard flu shot in a Phase 3 clinical trial…

Moderna's mRNA flu vaccine is more effective than the standard shot in a late-stage trial

The efficacy of flu shots is not always the same and it’s not always optimal. Some years, they can reduce the risk of illness by as little as 20% to 30%. Messenger RNA technology, or mRNA, is widely seen as a promising way to improve the effectiveness of flu shots, partly because it can be updated more quickly to match circulating strains. New results published Wednesday in the New England Journal of Medicine found Moderna’s mRNA flu vaccine gav…

Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigational Seasonal Influenza Vaccine, mRNA-1010

Regulatory filings are under review in the U.S., Europe, Canada and Australia, with potential approvals expected to begin in 2026

Moderna’s mRNA flu vaccine more effective than standard shot in late-stage trial

Moderna’s mRNA flu vaccine gave more protection against illness than the standard flu shot in a phase 3 clinical trial, according to published results.